ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,674Medicare Part D Prescriptions Filled, Including Refills

Rank: 94 out of 617

$370K Total Retail Price of All Prescriptions

Rank: 175 out of 617

339 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
42% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 339 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

17% of this provider’s 339 patients filled at least one prescription for a schedule three drug, compared to an average of 11%.

Risky Drugs to Seniors

2% of this provider’s 9,645 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

16% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$35 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

31 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
WARFARIN SODIUM 662 643 1 7
LEVOTHYROXINE SODIUM 533 505 2 1
FUROSEMIDE 523 508 3 4
POTASSIUM CHLORIDE 371 360 4 10
CITALOPRAM HBR 367 309 5 18
POLYETHYLENE GLYCOL 3350 359 349 6 32
OMEPRAZOLE 355 291 7 3
LISINOPRIL 342 311 8 5
GABAPENTIN 284 247 9 16
HYDROCODONE-ACETAMINOPHEN 270 231 S3 10 8
METFORMIN HCL 236 187 11 9
TRAMADOL HCL 230 208 12 15
ATENOLOL 195 192 13 17
SIMVASTATIN 166 158 14 2
SPIRONOLACTONE 163 153 15 42
METOPROLOL SUCCINATE 155 155 16 12
METOPROLOL TARTRATE 154 126 17 11
LOVASTATIN 116 111 18 57
AMLODIPINE BESYLATE 113 103 19 6
HYDROCHLOROTHIAZIDE 113 94 19 13
MELOXICAM 106 88 21 24
TAMSULOSIN HCL 104 104 22 26
LOSARTAN POTASSIUM 103 80 23 22
ATORVASTATIN CALCIUM 100 92 24 14
CARVEDILOL 100 90 24 19
DONEPEZIL HCL 98 98 26 30
ZOLPIDEM TARTRATE 98 97 26 23
DOXAZOSIN MESYLATE 83 80 28 79
ADVAIR DISKUS 76 64 29 38
RISPERIDONE 73 73 30 71
PAROXETINE HCL 68 66 31 62
LANTUS 67 64 32 39
PREDNISONE 66 60 33 31
ATENOLOL-CHLORTHALIDONE 64 52 34 142
CLONIDINE HCL 63 63 35 55
SERTRALINE HCL 63 62 35 20
CRESTOR 62 62 37 28
NAMENDA 61 61 38 35
BYSTOLIC 60 60 39 64
CIPROFLOXACIN HCL 58 55 40 60
MIRTAZAPINE 56 54 41 50
AZITHROMYCIN 54 48 42 70
GLYBURIDE 54 54 R 42 84
VENLAFAXINE HCL ER 54 47 42 76
IPRATROPIUM BROMIDE 54 54 42 136
IPRATROPIUM-ALBUTEROL 54 54 42 151
RANITIDINE HCL 53 43 47 40
ALENDRONATE SODIUM 53 38 47 25
AMIODARONE HCL 51 51 49 129
CEPHALEXIN 51 45 49 68
TRIAMCINOLONE ACETONIDE 51 50 49 102
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 24, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.